GlassScriptPhysician profile
Ronald E Frenkel
NPI 1649280553
$3,873.06
in general payments reported to CMS, 2019-2025
32 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.42 · 2020: $100 · 2021: $204 · 2022: $320 · 2023: $2,358 · 2024: $523 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,911 · Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,910.86 |
| Food and Beverage | $1,241.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,120.66 | 2020-2025 | Lensx, Rocklatan, Clareon Panoptix Pro |
| Regeneron Healthcare Solutions, INC. | $418.73 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $235.61 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $215.70 | 2022-2025 | Syfovre |
| Abbvie INC. | $161.86 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $80.74 | 2019-2021 | |
| Astellas Pharma US INC | $60.96 | 2023-2024 | Izervay |
| Bausch & Lomb Americas INC. | $60.87 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $52.37 | 2024 | Idose |
| Johnson & Johnson Surgical Vision, INC. | $49.13 | 2023-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Dompe US, INC. | $47.74 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $45.52 | 2022-2024 | Ryzumvi, Tyrvaya |
| Horizon Therapeutics Plc | $45.43 | 2021-2022 | |
| Sight Sciences, INC. | $45.12 | 2021-2024 | Omni Surgical System |
| Allergan, INC. | $45.09 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.86 | 2020 | |
| Alimera Sciences, INC. | $36.56 | 2022 | |
| Mallinckrodt Hospital Products INC. | $23.54 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.11 | 2024 | |
| Rayner Intraocular Lenses Limited | $22.89 | 2025 | Omidria |
| Kala Pharmaceuticals, INC. | $22.71 | 2021 | |
| Ocular Therapeutix, INC. | $14.86 | 2021 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Frenkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.